A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study Assessing the Safety, Tolerability and Pharmacokinetics of Two Different Doses of LBR-101 Given Intravenously and Subcutaneously
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2015
At a glance
- Drugs Fremanezumab (Primary) ; Fremanezumab (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors Labrys Biologics; Teva Pharmaceutical Industries
- 08 Jan 2014 Status changed from active, no longer recruiting to completed, according to a Labrys Biologics media release.
- 20 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Nov 2013 New trial record